An Arizona-based health-care company is turning heads Wednesday morning after announcing positive two-year follow-up data for the Company’s StemSpine® pilot study. According to the release, the data shows significant efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported. Shares of Creative Medical Technology Holdings Inc. (NASDAQ:CELZ) is bid up massively on the news.
Creative Medical is a biotechnology holding company focused on regenerative medicine. It is formed for the purpose of creating and licensing intellectual property in the area of amniotic fluid-derived stem cells for therapeutic applications. Its core activity is stem cell research and the development of applications for use to treat male and female sexual dysfunction, infertility, miscarriages, and related issues.
Traders are extremely optimistic on the news as shares of CELZ are currently bid up at $3.12/share (+83.53% implied open for sellers) at the time of writing. As we head into the final ten minutes of premarket, it’ll be exciting to see how the regular session reacts to this news!
